drugset / Trial / NCT06871644
Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases
NaSingle-groupOpen-labelTreatment
Summary
The primary objective was to evaluate the safety of CD7 CAR-T cells for the treatment of subjects with relapsed/refractory AID. CD7 CAR-T cells were infused in a single infusion in subjects who were screened after signing an informed consent form and undergoing single nucleus cell collection and pretreatment, and blood was collected before and after the infusion for pharmacokinetic, pharmacodynamic, immunogenicity, and safety evaluations.
Timeline
- Start
- 2025-03-18
- Primary completion
- 2026-03-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD7 CAR-T cells | Cell therapy | 2.5e+07 cells | — |
| Subject | CD7 CAR-T cells | Cell therapy | 1e+08 cells | — |
| Subject | CD7 CAR-T cells | Cell therapy | 2e+08 cells | — |